Sarepta Therapeutics
PharmaSarepta Therapeutics is a pharmaceutical company focused on Immunology, Dermatology. Key products include EXONDYS 51.
FDA Novel Drug Designations
(2016-2021)See 3 novel approvals →
Sarepta Therapeutics's Key Drugs
Sarepta Therapeutics's core commercial portfolio centers on VYONDYS 53, EXONDYS 51, AMONDYS 45, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
Sarepta Therapeutics's Recent FDA Approvals
New NDA/BLA approvals for Sarepta Therapeutics over the last two years — novel drugs only, excluding generics and label supplements.
Sarepta Therapeutics's Therapeutic Areas
Sarepta Therapeutics's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Sarepta Therapeutics's Top Competitors
Sarepta Therapeutics's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Sarepta Therapeutics Pipeline Snapshot
Sarepta Therapeutics has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VYONDYS 53 leads revenue
- • 4 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/9 completed
- • Speed: 39 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2016-09-19
- Latest
- 2026-01-06
- Applications
- 4
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges